Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dotarem Clear all
Completed No phase listed Observational Accepts healthy volunteers

Dotarem Evaluation for Myocardial Perfusion CMR

NCT03937921
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Magnetic Resonance Imaging
Interventions
Gadavist 15Ml Solution for Injection
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

NCT05417776
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
[68Ga]CBP8, Dotarem
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gadolinium Retention in Human Bone Tissue in Pediatric Patients

NCT03337594
View directory record Official record
Conditions
Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
Interventions
Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
Drug · Procedure
Lead sponsor
Donna Roberts
Other
Eligibility
Up to 18 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational Results available

Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration

NCT01467271
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Guerbet
Industry
Eligibility
Not listed
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Saginaw, Michigan • St Louis, Missouri • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 20, 2026, 2:27 PM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640
View directory record Official record
Conditions
Steno-occlusive Disease
Interventions
gadopiclenol, Gadoterate meglumine (Dotarem)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging for Pulmonary Fibrosis

NCT06532071
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

NCT05937776
View directory record Official record
Conditions
Glioma
Interventions
Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Withdrawn Phase 4 Interventional

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

NCT02163005
View directory record Official record
Conditions
Contrast Media Allergy
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
56 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873
View directory record Official record
Conditions
Diagnostic Self Evaluation, Central Nervous System Diseases
Interventions
Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01012674
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01010932
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Gadoterate in Patients With Renal Dysfunction

NCT02382380
View directory record Official record
Conditions
Renal Dysfunction
Interventions
Gadoterate, No Gadoterate
Drug · Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Eovist vs. Dotarem Healthy Volunteer MRI

NCT02431598
View directory record Official record
Conditions
Transient Severe Arterial Phase Motion
Interventions
gadoxetate disodium, gadoterate dimeglumine, Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

NCT05199792
View directory record Official record
Conditions
Vascular Diseases
Interventions
Dotarem
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 20, 2026, 2:27 PM EDT
Terminated Phase 3 Interventional Results available

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

NCT00980681
View directory record Official record
Conditions
Renal Disease
Interventions
Dotarem, Time of Flight
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 20, 2026, 2:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 20, 2026, 2:27 PM EDT
Withdrawn Phase 4 Interventional

Use of Gadolinium in CT Pulmonary Angiography

NCT02234375
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 2:27 PM EDT
Completed No phase listed Observational

Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age

NCT02609919
View directory record Official record
Conditions
Adverse Reaction to Drug, Allergic Reaction to Contrast Media
Interventions
Gadoteric Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
Up to 2 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 20, 2026, 2:27 PM EDT